Citius Pharmaceuticals is trading 6.70% up at $0.52 today after its majority-owned subsidiary, Citius Oncology, announced a significant expansion of its LYMPHIR commercial team and reported strong market adoption. - Citius Oncology has added 21 commercial field-based professionals and eight medical science liaisons to support the U.S. launch of LYMPHIR, with full deployment expected by August 2026. - The company also reported achieving near 100% payer coverage for LYMPHIR and a growing number of treatment accounts placing orders for the drug.